郭鹏

<https://dslx.ustc.edu.cn/?menu=expert_paper_detail&expertid=6569871>

单位：中国科学院基础医学与肿瘤研究所

地址：浙江省杭州市钱塘区东方街150号

邮编：310018

电话：

个人主页： http://dslx.ustc.edu.cn/?menu=expert\_paper&expertid=6569871

个人简历

研究方向

生物医学工程

癌症药物

招生信息

论文专著

1) A rationally designed ICAM1 antibody drug conjugate for pancreatic cancer - A rationally designed ICAM1 antibody drug conjugate for pancreatic cancer - 2023

2) Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration - Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration - 2024

3) The promise and challenges of combination therapies with antibody‑drug conjugates in solid tumors - The promise and challenges of combination therapies with antibody‑drug conjugates in solid tumors - 2024

4) ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma - ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma - 2023

5) Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma - Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma - 2023

Guo Peng

<https://dslx.ustc.edu.cn/?menu=expert_paper_detail&expertid=6569871>

Affiliation: Institute of Basic Medicine and Cancer, Chinese Academy of Sciences

Address: No. 150, Dongfang Street, Qiantang District, Hangzhou City, Zhejiang Province

Postal Code: 310018

Phone:

Personal Homepage: http://dslx.ustc.edu.cn/?menu=expert\_paper&expertid=6569871

Personal Resume

Research Directions:

Biomedical Engineering

Cancer Drugs

Admissions Information

Papers and Monographs:

1) A rationally designed ICAM1 antibody drug conjugate for pancreatic cancer - 2023

2) Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration - 2024

3) The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors - 2024

4) ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma - 2023

5) Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma - 2023